Cargando…

Cerebrovascular disease promotes tau pathology in Alzheimer’s disease

Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzhei...

Descripción completa

Detalles Bibliográficos
Autores principales: Laing, Krystal K, Simoes, Sabrina, Baena-Caldas, Gloria P, Lao, Patrick J, Kothiya, Milankumar, Igwe, Kay C, Chesebro, Anthony G, Houck, Alexander L, Pedraza, Lina, Hernández, A Iván, Li, Jie, Zimmerman, Molly E, Luchsinger, José A, Barone, Frank C, Moreno, Herman, Brickman, Adam M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660042/
https://www.ncbi.nlm.nih.gov/pubmed/33215083
http://dx.doi.org/10.1093/braincomms/fcaa132
_version_ 1783608924747857920
author Laing, Krystal K
Simoes, Sabrina
Baena-Caldas, Gloria P
Lao, Patrick J
Kothiya, Milankumar
Igwe, Kay C
Chesebro, Anthony G
Houck, Alexander L
Pedraza, Lina
Hernández, A Iván
Li, Jie
Zimmerman, Molly E
Luchsinger, José A
Barone, Frank C
Moreno, Herman
Brickman, Adam M
author_facet Laing, Krystal K
Simoes, Sabrina
Baena-Caldas, Gloria P
Lao, Patrick J
Kothiya, Milankumar
Igwe, Kay C
Chesebro, Anthony G
Houck, Alexander L
Pedraza, Lina
Hernández, A Iván
Li, Jie
Zimmerman, Molly E
Luchsinger, José A
Barone, Frank C
Moreno, Herman
Brickman, Adam M
author_sort Laing, Krystal K
collection PubMed
description Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer’s pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer’s disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer’s Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer’s disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer’s disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer’s disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer’s Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice.
format Online
Article
Text
id pubmed-7660042
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76600422020-11-18 Cerebrovascular disease promotes tau pathology in Alzheimer’s disease Laing, Krystal K Simoes, Sabrina Baena-Caldas, Gloria P Lao, Patrick J Kothiya, Milankumar Igwe, Kay C Chesebro, Anthony G Houck, Alexander L Pedraza, Lina Hernández, A Iván Li, Jie Zimmerman, Molly E Luchsinger, José A Barone, Frank C Moreno, Herman Brickman, Adam M Brain Commun Original Article Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer’s pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer’s disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer’s Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer’s disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer’s disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer’s disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer’s Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice. Oxford University Press 2020-08-19 /pmc/articles/PMC7660042/ /pubmed/33215083 http://dx.doi.org/10.1093/braincomms/fcaa132 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Laing, Krystal K
Simoes, Sabrina
Baena-Caldas, Gloria P
Lao, Patrick J
Kothiya, Milankumar
Igwe, Kay C
Chesebro, Anthony G
Houck, Alexander L
Pedraza, Lina
Hernández, A Iván
Li, Jie
Zimmerman, Molly E
Luchsinger, José A
Barone, Frank C
Moreno, Herman
Brickman, Adam M
Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title_full Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title_fullStr Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title_full_unstemmed Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title_short Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
title_sort cerebrovascular disease promotes tau pathology in alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660042/
https://www.ncbi.nlm.nih.gov/pubmed/33215083
http://dx.doi.org/10.1093/braincomms/fcaa132
work_keys_str_mv AT laingkrystalk cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT simoessabrina cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT baenacaldasgloriap cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT laopatrickj cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT kothiyamilankumar cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT igwekayc cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT chesebroanthonyg cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT houckalexanderl cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT pedrazalina cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT hernandezaivan cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT lijie cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT zimmermanmollye cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT luchsingerjosea cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT baronefrankc cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT morenoherman cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT brickmanadamm cerebrovasculardiseasepromotestaupathologyinalzheimersdisease
AT cerebrovasculardiseasepromotestaupathologyinalzheimersdisease